Lakefront Biotherapeutics (LKFT) Gross Margin (2016 - 2026)

Lakefront Biotherapeutics (LKFT) has 11 years of Gross Margin data on file, last reported at 25.95% in Q1 2026.

• Gross Margin for Q1 2026 came in at 25.95%, down 5574.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 97.95% (up 1069.0% YoY), and the FY2025 annual result was 97.33%, up 997.0% from the prior year.
• Gross Margin declined to 25.95% in Q1 2026 per LKFT's latest filing, from 99.95% in the prior quarter.
• Over five years, Gross Margin peaked at 120.13% in Q2 2025 and troughed at 25.95% in Q1 2026.
• A 5-year average of 90.92% and a median of 97.28% in 2023 frame the typical range for Gross Margin.
• The sharpest annual moves came in 2022 and 2026: Gross Margin surged 3336281 bps in 2022, then slumped 5574 bps in 2026.
• A 5-year view of Gross Margin shows it stood at 102.45% in 2022, then dropped by 6 bps to 96.69% in 2023, then dropped by 1 bps to 95.47% in 2024, then grew by 5 bps to 99.95% in 2025, then tumbled by 74 bps to 25.95% in 2026.
• Business Quant data shows LKFT's Gross Margin at 25.95% in Q1 2026, 99.95% in Q4 2025, and 59.68% in Q3 2025.